Charles W. Newhall III - Nov 11, 2024 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Stock symbol
SUPN
Transactions as of
Nov 11, 2024
Transactions value $
-$205,168
Form type
4
Date filed
11/12/2024, 04:15 PM
Previous filing
Feb 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $183K +20K +16.53% $9.13 141K Nov 11, 2024 Direct
transaction SUPN Common Stock Sale -$388K -10.7K -7.59% $36.24 130K Nov 11, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Director Stock Option (Right to Buy) Options Exercise $0 -20K -100% $0.00 0 Nov 11, 2024 Common Stock 20K $9.13 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 3, 2025
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.02 to $36.46. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.